
First patient dosed in glioblastoma gene therapy trial
The first patient has been dosed in the Phase I/II clinical trial of a gene therapy for glioblastoma (GBM). TGX-007, developed by oncology company Trogenix, is a dual-payload adeno-associated virus (AAV)-based gene therapy. TGX-007 harnesses Trogenix’s proprietary Synthetic Super-Enhancer (SSE) technology to exploit the core cancer cell identity. The… Read More


